First author of the lab’s inaugural biliary tract cancer study, identifying PI3K-pathway activation as a molecular determinant of chemotherapy benefit in advanced BTC (Clinical and Molecular Hepatology, 2026).
First author of the lab’s inaugural biliary tract cancer study, identifying PI3K-pathway activation as a molecular determinant of chemotherapy benefit in advanced BTC (Clinical and Molecular Hepatology, 2026).